Gm.Cd40L Vaccine
Adenocarcinoma of the Lung
H. Lee Moffitt Cancer Center and Research InstitutevaccinePhase 1/2Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 89/ 100
Competitive context
68 Active assets in the Adenocarcinoma of the Lung cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin Guangdong Association of Clinical Trials | Phase 3 | BBB |
Cyclophosphamide Anusha Kalbasi | Phase 2 | BBB |
Nivolumab Emory University | Phase 3 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II Guangdong Association of Clinical Trials | Phase 3 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II National Cancer Institute (NCI) | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Gm.Cd40L Vaccine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →